Drugs / 17-N-allylamino-17-demethoxygeldanamycin
17-N-allylamino-17-demethoxygeldanamycin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00100997 | Oct 2004 → Oct 2006 | leukemia | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT00303797 Background | Dec 2005 → May 2010 | B-cell chronic lymphocytic leukemia, plasma cell myeloma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00082966 Background | Mar 2004 → Mar 2007 | Hodgkin's lymphoma, lymphocytic depletion, Hodgkin's lymphoma, mixed cellularity, nodular sclerosis classical Hodgkin lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 17-N-allylamino-17-demethoxygeldanamycin | “RATIONALE: Drugs used in chemotherapy, such as 17-N-allylamino-17-demethoxygeldanamycin, work in different ways to stop the growth of cancer cells, either by killing the cells...” NCT00100997 ↗ |
| Known as | 17-(Allylamino)-17-Demethoxygeldanamycin | “A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Intravenously Administered CNF1010...” NCT00100997 ↗ |
| Known as | 17-AAG | “Patients receive 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) IV over 15 minutes or 1 hour (depending on the dose administered) once on days 1, 4, 8, 11, 15, 18, 22, and 25.” NCT00100997 ↗ |
| Known as | CNF1010 | “A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Intravenously Administered CNF1010...” NCT00100997 ↗ |
| Action | Inhibit | “It may also stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.” NCT00100997 ↗ |
| Route | Intravenous | “Given IV” NCT00082966 ↗ |